T-E Meds is developing a number of new ADC/ARC drug candidates based on our T-E pharmaceutical and multi-arm linker platforms.
While our T-E pharmaceuticals are new drug entities, the targeting and/or the effector elements in many of these drug candidates are based on existing drugs, which have been approved for clinical uses or studied extensively.
Our goal is to create a class of new ADC/ARC drugs and to improve many existing drugs with higher efficacy and safety (E/S) profiles.
The product candidates command substantial differentiation from existing drugs and have potential to be the best in an existing class or the first in a new class.
The current platform technology and drug development timeline are as follows:
